................... 12 LIST OF FIGURES .................................................................................................................13 APPENDI CES .........................................................................................................................13 SCHEDUL E OF ACTIVITI ES................................................................................................14 1. INTRODUCTION ...............................................................................................................39 1.1. Mechanism of Action/I ndication .............................................................................39 1.2. Background and Rationale ......................................................................................39 1.2.1. Non -Small Cell L ung Cancer Treatment Overview ...................................40 1.3.VBIR - 2 ....................................................................................................................43 1.3.1. Rationale for t he Components of VBIR -2 ..................................................43 1.3.2. Selection of Vaccine Antigens (MUC1, MSLN, TERT) ............................44 1.4. Nonclinical Safet y ...................................................................................................47 1.4.1. Nonclinical Toxicity Study for VBIR - 2 .....................................................47 1.5. Clinical Overview ...................................................................................................49 1.6. Dose Rationale ........................................................................................................49 1.6.1. Clinical AdC68 (PF -06871923) Dosing .....................................................49 1.6.2. Clinical pDNA (PF -0681925) Dosing ........................................................50 1.6.3. Clinical Tremelimumab (PF -06753388) Dosing ........................................50 1.6.4. Clinical Sasanlimab Dosing ........................................................................51 1.6.4.1. Sasanlimab Clinical Experience B8 011001 (NCT02573259) ................................................................................51 1.6.4.2. Sasanlimab Clinical Experience in B7791001 (NCT#02616185) ..............................................................................52 1.6.5. Combination of CTL A -4 and PD- 1 Monoclonal Antibodies: Safety Findings ............................................................................................................53 1.6.6. Clinical Dosing VBIR - 2 ................................